###### Strengths and limitations of this study

-   This meta-analysis is more rigorous than the previous meta-analyses, including trials, with more reliable results.

-   The included trials were all randomised controlled trials, and the overall quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation.

-   Only seven studies were eligible for inclusion in this meta-analysis.

-   Due to the limited number of the eligible trials and that the sample size of each trial was fairly small, a direct assessment of the antifracture efficacy was not performed.

Introduction {#s1}
============

Osteoporosis is characterised by low bone mass and a microarchitectural deterioration of the bone tissue.[@R1] Due to the high mortality and morbidity, osteoporosis-related fractures have become a formidable public health threat.[@R2] In the USA alone, the cost of fractures related to osteoporosis in 2005 was US\$16.9 billion, and it is estimated that this figure would increase to US\$25.3 billion by 2025.[@R5]

To date, a range of pharmacological interventions is available for the treatment of osteoporosis. Depending on their mechanism of action, antiosteoporosis medications can be classified into either antiresorptive agents or anabolic agents. Antiresorptive agents include bisphosphonates, hormone replacement therapy, raloxifene, denosumab and calcitonin. Anabolic agents include the full-length molecule parathyroid hormone (PTH 1--84) and teriparatide (PTH 1--34). Despite various drugs, there is no evidence that single use of any agent can restore skeletal integrity in most patients with established osteoporosis.[@R6] Theoretically, the 'ideal' antiosteoporosis drug would increase the new bone formation and inhibit bone resorption.[@R7] Given this absence of the 'ideal' therapy, the concomitant combination therapy of anabolic and antiresorptive agents has been proposed as alternative. The rationale for combining anabolic and antiresorptive agents is that if bone formation is stimulated by an anabolic agent while bone resorption is inhibited by an antiresorptive agent, the concomitant combination therapy might attain superior bone mass and strength effects compared with monotherapy.[@R8]

Since bisphosphonates are the most commonly used antiresorptive medications for the treatment of osteoporosis,[@R9] the concomitant combination therapy of anabolic agents and bisphosphonates was initially thought to be a promising approach. However, results of the concomitant use of bisphosphonates and anabolic agents were mixed.[@R10] The earlier trials did not confirm this positive effect,[@R10] but trials in recent years reported a positive effect of the combination therapy.[@R12]

To date, it remains unclear (1) whether bisphosphonates in concomitant combination with anabolic agents could produce more benefits than anabolic monotherapy, (2) whether the dose and type of antiosteoporosis agents could affect the effect of concomitant combination therapy and (3) when the combination therapy should be used. Thus, a meta-analysis was necessary to summarise the current evidence. Two meta-analyses[@R20] on the topic have been published, indicating that the combination therapy was not superior to monotherapy with anabolic agent alone,[@R20] and even reduced the ability of anabolic therapy to increase the bone mineral density (BMD) at the lumbar spine, femoral neck and total hip.[@R21] However, it should be noted that some serious problems existed in these two studies, such as (1) missing some key trials,[@R20] which determined the combination therapy had a higher increase in BMD than the monotherapy[@R13]; (2) using repeated data[@R20]; (3) including trials which did not meet their inclusion criteria.[@R20] These problems greatly reduced the credibility of their results.

Therefore, this meta-analysis of randomised controlled trials (RCTs) aimed to determine whether the concomitant combination therapy of anabolic agents and bisphosphonates produces more effects on BMD than an anabolic agent alone in patients with osteoporosis.

Methods {#s2}
=======

This meta-analysis protocol was registered on the International Prospective Register of Systematic Reviews (CRD42016041335), and was developed following the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@R22] This study was not a human or animal experiment, so no ethical approval was required.

Study inclusion and exclusion criteria {#s2a}
--------------------------------------

Studies included in this meta-analysis meet the following inclusion criteria: (1) study design: RCT with a duration of at least 6 months; (2) study subjects: patients diagnosed with osteoporosis; (3) study intervention: patients in the treatment group received a concomitant combination therapy of anabolic agents and bisphosphonates, whereas patients in the control group received monotherapy with anabolic agents; (4) outcome measure: the outcome measurement included the mean per cent increases in BMD (measured by dual-energy X-ray absorptiometry) of the lumbar spine, femoral neck and total hip. Owing to the potential higher risk of osteosarcoma, treatment of anabolic drugs was recommended less than 24 months (the full period).[@R23] Moreover, owing to the subsequent resistance to anabolic agents, it was suggested that to increase BMD, anabolic agents might best be used for periods (the optimal period) of 6 to 12 months or less.[@R25] Thus, the primary outcome of interest was the BMD changes from an optimal period (6 to 12 months). The secondary outcome was the BMD changes from the full period (18 to 24 months). Exclusion criteria included non-RCTs or studies published as abstracts, review articles, editorials and letters.

Data sources and search {#s2b}
-----------------------

We systematically searched MEDLINE, EMBASE and the Cochrane Library from 1 January 1980 until 1 August 2016, with no language restrictions. Additionally, relevant studies were obtained by scanning reference lists of articles identified in the initial searches, relevant meta-analyses and systematic reviews.

The literature search was performed in duplicate by two independent authors (SL, HL). Search strategies were developed using text words as well as medical subject headings associated with terms relevant to 'osteoporosis', 'teriparatide', 'parathyroid hormone', 'bisphosphonate' together with 'randomized control trial'. The full search strategies used in MEDLINE, EMBASE and Cochrane Library are provided in online [supplementary file S1](#SP1){ref-type="supplementary-material"}.
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Study selection {#s2c}
---------------

Our search records were imported into ENDNOTE X7 reference management software, and two authors (SL, HL) independently reviewed the titles and abstracts of the literature searches. Trials that did not meet the eligibility criteria were excluded. After excluding the duplicated and obviously irrelevant articles, the remaining studies were further reviewed by full-text reading to ascertain whether they should be included by the same eligibility criteria. For duplicate articles or publications reporting the same data in multiple articles, only the study with the most complete data and the longest follow-up would be included. After completion, both authors met and reviewed their selections for agreement. Any disagreements were resolved by discussion or by seeking an independent third author (ZL).

Data extraction {#s2d}
---------------

A standard data extraction form was created using Microsoft Excel 2016 to collect data of interest. The major categories of variables to be coded were: (1) study characteristics; (2) participant characteristics; (3) type of intervention (type, dose, duration) and (4) outcome characteristics. Information was carefully extracted from all the eligible publications independently by two authors (SL, HL), and disagreements were resolved through discussion or by seeking an independent third author (ZL). If the original data were not available, we calculated the data through the available coefficients. For example, we computed the mean from median and SD for SE, IQR or P values, according to the methods described in the Cochrane Handbook.

Risk of bias assessment {#s2e}
-----------------------

Two authors (SL, HL) independently assessed the risk of bias using the Cochrane risk-of-bias tool.[@R26] The Cochrane risk-of-bias tool assessed bias across the following seven domains: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting; (7) other bias. Each domain was determined as 'low risk', 'unclear risk' or 'high risk'. For the first four domains, if the trial clearly reported adequate methods, it was regarded as a low risk of bias. If the trial did not clearly report the methods, it was regarded as an unclear risk of bias. If the trial reported inadequate methods, it was regarded as a high risk of bias. For the incomplete outcome data, we considered ≥20% loss to follow-up to represent a high risk of bias. For the selective reporting, we assessed it by comparing each publication with its corresponding published protocol, when available. For other sources of bias, we considered major imbalances in key baseline characteristics represent a high risk of bias. Any disagreements were resolved through discussion, and sometimes with another reviewer (ZL) if necessary.

Statistical analysis {#s2f}
--------------------

Both primary outcomes and secondary outcomes of this study were changes in BMD, and all of them were continuous data, so the effect sizes were reported as standardised mean differences (SMDs) and 95% CIs, using the generic inverse variance (IV) methods.

The meta-analysis was performed using a random-eﬀects model, which provided more conservative estimated effects. To assess the heterogeneity of the results from individual studies, Cochrane's Q statistic, the I^2^ statistic (I^2^\>50% as a threshold indicates significant heterogeneity) and P values (P\<0.10 as a threshold indicates significant heterogeneity) were used.[@R27] The preplanned subgroup analyses were performed to explore the sources of heterogeneity based on the different types of antiosteoporotic agents or the different dose of anabolic agents. The publication bias was assessed visually with a funnel plot. Additional sensitivity analyses for the primary outcomes were done to explore the heterogeneity by omitting specific trials from the overall analysis. The meta-analysis was analysed using the statistical software packages Review Manager (V.5.3) and Comprehensive Meta-Analysis (V.2.0). All the tests were two-tailed and a P value of \<0.05 was deemed statistically significant.

Quality of evidence {#s2g}
-------------------

Two authors (SL, HL) independently evaluated the quality of evidence for primary and secondary outcomes according to the guidelines of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) for risk of bias, inconsistency, indirectness, imprecision and publication bias.[@R28] Each assessment result was rated as very low, low, moderate or high. Summary tables were constructed using GRADE Profiler (V.3.6).

Results {#s3}
=======

Search results {#s3a}
--------------

A total of 1187 articles were obtained through electronic and hand searches. After 460 duplicates were removed, the titles and abstracts of 727 records were reviewed, 713 records were excluded for not meeting the inclusion criteria and thus the remaining 14 articles were retrieved, all written in English, for further assessment. Seven trials were excluded due to reports of repeated data,[@R10] not about 'combination therapy'[@R29] or the control group was not monotherapy.[@R25] Seven trials[@R12] fulfilled our inclusion criteria and were included in our meta-analysis ([figure 1](#F1){ref-type="fig"}).

![Flow diagram showing the process of literature selection.](bmjopen-2016-015187f01){#F1}

Characteristics of included trials {#s3b}
----------------------------------

The main characteristics of the included trials are summarised in [table 1](#T1){ref-type="table"}. These trials were published from 2003 to 2013 and involved totally 747 patients, with the sample sizes ranging from 19 to 275. The anabolic agents included PTH 1--34 (teriparatide) and PTH 1--84. There were two different doses (20 and 40 µg) of PTH 1--34 included in this study. Currently, the approved dose of PTH 1--34 for the treatment of osteoporosis was 20 µg. The bisphosphonates included alendronate (ALN), risedronate and zoledronate. Bisphosphonates were used with a conventional dose for the treatment of osteoporosis. The duration of treatment was from 9 to 24 months. All patients received oral calcium and vitamin D supplements daily.

###### 

Characteristics of the included randomised controlled trials

  Study (year)                       Sex      Basic intervention                                       Experimental group (combination therapy)   Control group (monotherapy or sequential therapy)   Duration (month)                                                                                         
  ---------------------------------- -------- -------------------------------------------------------- ------------------------------------------ --------------------------------------------------- ------------------------------------------------- ----- ------------ ----------------------------------- ----
  Black *et al*[@R18] (2003)         Female   500 mg calcium, 400 IU vitamin D daily                   59                                         70.2 (6.8)                                          ALN 10 mg/day plus PTH 1--84 100 µg/day           119   69.4 (7.3)   PTH 1--84 100 µg/day plus placebo   12
  Finkelstein *et al*[@R17] (2003)   Male     1000 to 1200 mg calcium, 400 IU vitamin D daily          25                                         58 (8)                                              ALN 10 mg/day plus TPTD 40 µg/day                 20    57 (9)       TPTD 40 µg/day alone                24
  Cosman *et al*[@R16] (2009)        Female   at least 500 mg calcium, 400 to 800 IU vitamin D daily   52                                         67.8 (1.4)                                          ALN 10 mg/day or 70 mg/week plus TPTD 20 µg/day   50    69.1 (1.4)   TPTD 20 µg/day alone                18
  Finkelstein *et al*[@R15] (2010)   Female   1000 to 1200 mg calcium, 400 IU vitamin D daily          20                                         62 (7)                                              ALN 10 mg/day plus TPTD 40 µg/day                 20    65 (7)       TPTD 40 µg/day alone                24
  Cosman, *et al*[@R14] (2011)       Female   1000 to 1200 mg calcium, 400 to 800 IU vitamin D daily   137                                        65.0 (8.8)                                          ZOL 5 mg/year plus TPTD 20 µg/day                 138   63.8 (9.1)   TPTD 20 µg/day plus oral placebo    12
  Muschitz *et al*[@R13] (2013)      Female   1000 mg calcium, 800 IU vitamin D daily                  41                                         71.6 (8.5)                                          ALN 70 mg/week plus TPTD 20 µg/day                47    71.7 (9.3)   TPTD 20 µg/day alone                9
  Walker *et al*[@R12] (2013)        Male     500 mg calcium, 400 IU vitamin D daily                   10                                         56.7 (4.9)                                          RIS 35 mg/week plus TPTD 20 µg/day                9     51.6 (3.9)   TPTD 20 µg/day plus oral placebo    18

ALN, alendronate; PTH, parathyroid hormone; RIS, risedronate; TPTD, teriparatide; ZOL, zoledronate.

Risk of bias assessment {#s3c}
-----------------------

[Figure 2](#F2){ref-type="fig"} summarises the details of risk of bias. Only one trial[@R18] did not clearly report the random sequence generation. Only two trials[@R12] clearly reported the allocation concealment. The treatment was not blinded to the participants in four trials.[@R13] Blinding of outcome assessment was adequately reported in all the included trials.[@R12] There was a low risk of attrition bias, reporting bias and other biases in all trials except for one[@R12] that had a small simple size (less than 30).

![Risk of bias graph. Risk of bias summary. '+" means low risk; '?" means unclear risk; '-" means high risk.](bmjopen-2016-015187f02){#F2}

The primary outcome: mean per cent changes in BMD of 6 to 12 months duration {#s3d}
----------------------------------------------------------------------------

This analysis involved five[@R12] trials with a total of 615 to 627 patients. The combination therapy demonstrated a significant advantage over a monotherapy in BMD improvement at the total hip (SMD 0.42; 95% CI 0.26 to 0.58, I^2^=0%, P\<0.01) and the femoral neck (SMD 0.30; 95% CI 0.14 to 0.46, I^2^=0%, P\<0.01), although the effect of the combination therapy was equal to the monotherapy at the lumbar spine (SMD 0.13; 95% CI −0.17 to 0.43, I^2^=64%, P=0.39) ([figure 3](#F3){ref-type="fig"}).

![Forest plot for the bone mineral density variation of the 6 to 12 months duration. IV, inverse variance.](bmjopen-2016-015187f03){#F3}

The sensitivity analyses showed that one trial[@R16] significantly affected the pooled SMD at the lumbar spine, after it was omitted, and there was no significant heterogeneity (SMD 0.03; 95% CI −0.23 to 0.29, I^2^=43%, P=0.81) (see online [supplementary figure S1](#SP2){ref-type="supplementary-material"}). Then, a subgroup analysis was performed based on the different methods of combination therapy, and the results showed that among the four different methods of combination therapy, only the combination therapy with PTH 1--34 and ALN, based on two trials, was superior to the monotherapy (SMD 0.46; 95% CI 0.12 to 0.79, I^2^=16%, P\<0.01) (see online [supplementary figure S2](#SP2){ref-type="supplementary-material"}).
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The secondary outcome: mean per cent changes in BMD of 18 to 24 months duration {#s3e}
-------------------------------------------------------------------------------

Four trials[@R12] with 194 to 206 patients provided the BMD data and were included in the analysis ([figure 4](#F4){ref-type="fig"}). Compared with the anabolic agents alone, the combination therapy did not improve the BMD at the lumbar spine (SMD −0.06; 95% CI −0.71 to 0.59, I^2^=78%, P=0.85), the total hip (SMD, 0.05; 95% CI −0.71 to 0.82; I^2^=84%; P=0.89) and the femoral neck (SMD, −0.32; 95% CI −1.15 to 0.50; I^2^=86%; P=0.44).

![Forest plot for the bone mineral density variation of the 18 to 24 months duration.IV: inverse variance](bmjopen-2016-015187f04){#F4}

Subgroup analyses were performed based on the different dose of anabolic agents. Based on two trials, when a regular dose (20 µg) was used in the combination therapy, the BMD significantly increased at the lumbar spine (SMD 0.53; 95% CI 0.14 to 0.91, I^2^=0%, P\<0.01) and the total hip (SMD, 0.60; 95% CI 0.15 to 1.06, I^2^=13%, P=0.01), although the effect of the combination therapy was equal to the monotherapy at the femoral neck (SMD, 0.30; 95% CI −0.37 to 0.98, I^2^=50%, P=0.38) (see online [supplementary figure S3](#SP2){ref-type="supplementary-material"}).

In contrast, based on two trials, compared with a monotherapy with a double dose (40 µg) of PTH 1--34, the combination therapy had no advantage, and even reduced the ability of PTH 1--34 to increase the BMD at the lumbar spine (SMD −0.54; 95% CI −0.97 to −0.10, I^2^=0%, P=0.02), the total hip (SMD, −0.58; 95% CI −1.31 to 0.14, I^2^=63%, P=0.12) and the femoral neck (SMD, −1.02; 95% CI −2.02 to −0.02, I^2^=78%, P=0.38) (see online [supplementary figure S3](#SP2){ref-type="supplementary-material"}).

Publication bias {#s3f}
----------------

The publication bias of the primary outcomes was assessed through a visual inspection of the funnel plots ([figure 5](#F5){ref-type="fig"}). The funnel plots seemed to be asymmetric, suggesting the potential risk of publication bias.

![Funnel plot for publication bias. SMD, standardised mean difference.](bmjopen-2016-015187f05){#F5}

Grading the quality of evidence {#s3g}
-------------------------------

GRADE evidence profiles for each outcome are shown in [table 2](#T2){ref-type="table"}. The quality of evidence was judged as low for all the outcomes, which was downgraded from high due to the risk of bias and the potential reporting bias.

###### 

The Grading of Recommendations Assessment, Development and Evaluation evidence quality for each outcome

  Quality assessment                                                                                              Number of patients   Effect    Quality                    Importance                                                                                                                                
  --------------------------------------------------------------------------------------------------------------- -------------------- --------- -------------------------- ------------------------- ------------------------ ---------------- ----- ----- ----- --------------------------------------------- ----- -----------
  The optimal period (6 to 12 months)---lumbar spine (better indicated by higher values)                                                                                                                                                                                                                              
   5                                                                                                              Randomised trials    Serious   No serious inconsistency   No serious indirectness   No serious imprecision   Reporting bias   275   341   N/A   SMD 0.13 higher (0.17 lower to 0.43 higher)   Low   Critical
  The optimal period (6 to 12 months)---total hip (follow-up 9 to 18 months; better indicated by higher values)                                                                                                                                                                                                       
   5                                                                                                              Randomised trials    Serious   No serious inconsistency   No serious indirectness   No serious imprecision   Reporting bias   276   339   N/A   SMD 0.42 higher (0.26 to 0.58 higher)         Low   Critical
  The optimal period (6 to 12 months)---femoral neck (better indicated by higher values)                                                                                                                                                                                                                              
   5                                                                                                              Randomised trials    Serious   No serious inconsistency   No serious indirectness   No serious imprecision   Reporting bias   283   344   N/A   SMD 0.3 higher (0.14 to 0.46 higher)          Low   Critical
  The full period (18 to 24 months)---lumbar spine (better indicated by higher values)                                                                                                                                                                                                                                
   4                                                                                                              Randomised trials    Serious   No serious inconsistency   No serious indirectness   No serious imprecision   Reporting bias   100   94    N/A   SMD 0.06 lower (0.71 lower to 0.59 higher)    Low   Important
  The full period (18 to 24 months)---total hip (better indicated by higher values)                                                                                                                                                                                                                                   
   4                                                                                                              Randomised trials    Serious   No serious inconsistency   No serious indirectness   No serious imprecision   Reporting bias   100   94    N/A   SMD 0.05 higher (0.71 lower to 0.82 higher)   Low   Important
  The full period (18 to 24 months)---femoral neck (better indicated by higher values)                                                                                                                                                                                                                                
   4                                                                                                              Randomised trials    Serious   No serious inconsistency   No serious indirectness   No serious imprecision   Reporting bias   107   99    N/A   SMD 0.32 lower (1.15 lower to 0.5 higher)     Low   Important

N/A, not applicable; SMD, standardised mean difference.

Discussion {#s4}
==========

Main findings {#s4a}
-------------

We performed this meta-analysis of seven RCTs, involving a total of 747 patients, to determine whether the concomitant combination therapy of anabolic agents and bisphosphonates produces more effects on BMD than anabolic agents alone in patients with osteoporosis. The results of our pooled analysis indicated that compared with anabolic monotherapy, the combination therapy significantly improved the BMD at the total hip and femoral neck with a shorter term (6 to 12 months) and produced similar benefits on BMD for the longer term (18 to 24 months). In addition, subgroup analyses indicated that the effect of the combination therapy might be affected by the dose of anabolic agents.

Comparison with other studies {#s4b}
-----------------------------

Our results are consistent with the previous meta-analysis by Li *et al* of the fact that the combination therapy, in the first year, is superior to anabolic monotherapy for the BMD improvement at the total hip, but not for the lumbar spine BMD.[@R20] Meanwhile, our results are compatible with Wang *et al*[@R21] that the dosage (20 µg or 40 µg) of anabolic agents could affect the effect of combination therapy. Besides that, in agreement with the previous meta-analyses,[@R20] we also determine that, the combination therapy does not have an advantage than anabolic monotherapy for full-length treatment (18 to 24 months). Although both the number of included trials and the pooled results between our study and the previous meta-analysis[@R20] seem to be the same, it should be noted that there are some obvious differences between this study and the previous meta-analysis.

Compared with the meta-analysis by Li *et al*,[@R20] the differences are as follows: (1) Li *et al* only included trials with a minimum of 12-month follow-up, which led to one trial[@R13] (included in our study) not included in their meta-analysis. Moreover, one trial[@R16] (included in our study), which met the inclusion criteria of Li *et al*, was missed in their study. (2) Li *et al* considered 'a prospective RCT comparing PTH analogues combined with bisphosphonate versus PTH analogues alone' as one of the inclusion criteria for including trials. However, the comparator of one included trial[@R25] in their meta-analysis was not 'PTH analogues alone' but 'alendronate plus parathyroid hormone (1--34) subcutaneously daily for three 3-month cycles alternating with 3-month periods without parathyroid hormone'. (3) Among the included trials of Li *et al*, the trial Black *et al*[@R10] was a follow-up study of the trial Black *et al*,[@R18] for the outcome 'Mean Percent Change in Hip BMD'; including both these trials led Li *et al* to use repeated data in their meta-analysis. (4) For the subgroup analyses, Li *et al* used different time points (12 months or 24 months) to divide the groups. But, in our meta-analysis, we used different time periods to divide the groups (6 to 12 months or 18 to 24 months), which allowed us to use more data in the meta-analysis.

Compared with the meta-analysis by Zhang *et al*,[@R21] the differences are as follows: (1) three trials[@R12] (included in our study), which meet the inclusion criteria of Zhang *et al*, are missed in that study. (2) Zhang *et al* included trials should meet the inclusion criteria that 'patients in the treatment group received the combined therapy of PTH with alendronate, whereas patients in the control group received other treatment'. However, the treatment group of two included trials[@R32] in their meta-analysis is obviously not a combination therapy. Since one-third of the included trials (two of six) should not be included in the meta-analysis of Wang *et al*,[@R21] it may be the main reason why Wang *et al*[@R21] made a false conclusion, in contrary to the results of our study and Li *et al*,[@R20] that 'The lumbar spine BMD with combination therapy significantly decreased at the 12-month period, but increased over the 12-month period'.

Meanwhile, owing to these differences, our results, in contrary to the study of Li *et al*,[@R20] show that the combination therapy has an advantage of increasing the femoral neck BMD than anabolic monotherapy in the first year. Furthermore, although some of our results are consistent with Li *et al*[@R20] and Wang *et al*,[@R21] it should be noted that our study is more rigorous, making our results more credible than those two previous meta-analyses.

Implications for clinical practice {#s4c}
----------------------------------

Since anabolic agents were approved for a limited period (18 to 24 months), a sequential therapy was required due to the short duration. According to current evidence, as a part of the sequential therapy, using the combination therapy at the second step, switching from monotherapy (anabolic or antiresorptive agents) to combination therapy, might be appropriate.[@R10] Moreover, anabolic agents could be used concomitantly combined with other antiresorptive agents. The effects of combination therapy, also, seem to be affected by the potency of antiresorptive agents.[@R36] The simultaneous use of teriparatide and denosumab, a more potent antiresorptive agent than bisphosphonates, was more effective than monotherapy with anabolic agents,[@R37] and the BMD changes were larger than other combination strategies.[@R7] In agreement with our study, the simultaneous use of teriparatide and denosumab was only superior to monotherapy during the first year of treatment,[@R37] but not thereafter.[@R39] Thus, based on the current information, maybe, the concomitant combined therapy should be limited to 1 year.

Although current evidence does not yet support a change in clinical practice, in our clinical opinion, concomitant combination therapy may be appropriate for certain people with osteoporosis, for example, for people previously treated with antiosteoporotic treatment who yet continue to lose significant bone density while receiving monotherapy, additionally, for those patients who have a high risk of fracture, who have multiple prior fractures or who continue to fracture.

Limitations {#s4d}
-----------

This study has limitations. (1) The number of the included studies was small, which might lead to a risk of bias in reporting the results and limit a quantitative analysis of the publication bias. (2) There were some methodological limitations in the included trials, for instance, there was an unclear random sequence generation, an unclear allocation concealment, a lack of blindness of the patients and small sample sizes. (3) Since the sample size of each trial was fairly small, a direct assessment of the antifracture efficacy was not performed. (4) Due to the small number of studies, there was limited ability to consider subgroup analyses.

Implications for future research {#s4e}
--------------------------------

Further studies should focus on the following points. (1) Although BMD has been proven to be a reliable predictor of antifracture efficacy in patients treated with antiosteoporosis drugs,[@R40] further studies should pay more attention to both the BMD endpoints and the fracture endpoints. (2) Owing to the small number of studies, both the short-term (6 to 12 months) and the long-term (18 to 24 months) effect of the concomitant combination therapy still need further investigation with additional trials. (3) Although the concomitant combination therapy showed no benefit for the long-term (18 to 24 months), our subgroup analyses suggest that the teriparatide of 20 µg as combination therapy provided an advantage over the anabolic monotherapy over this long term. Further trials are needed to verify this outcome, and determine whether the effect of concomitant combination therapy is to be affected by the dose and type of anabolic agents. (4) Since the use of combination therapy carries a potential risk of more adverse events, future studies should investigate both the short-term and long-term adverse events of combination therapy. (5) To date, a variety of bisphosphonates were approved for the treatment of osteoporosis, which was more appropriate using in combination therapy is unclear. (6) Among the seven included trials, most patients included in this meta-analysis were osteoporotic women. Since the results were mainly carried out in women, whether the results presented in this meta-analysis are applicable to osteoporotic men need to be further studied.

Conclusions {#s5}
===========

Among patients with osteoporosis, compared with anabolic monotherapy, the concomitant combination therapy of anabolic agents and bisphosphonates significantly improved the BMD at the total hip and femoral neck with a shorter term (6 to 12 months) and produced similar benefits on BMD for the longer term (18 to 24 months). Also, the effect of concomitant combination therapy might be affected by the dose of anabolic agents.
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